

CORNERSTONE THERAPEUTICS INC  
Form 8-K  
April 01, 2010

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 30, 2010

Cornerstone Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction  
of incorporation)

000-50767

(Commission  
File Number)

04-3523569

(I.R.S. Employer  
Identification No.)

1255 Crescent Green Drive, Suite 250, Cary,  
North Carolina

27518

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

919-678-6611

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 30, 2010, Maria Paola Chiesi announced her decision not to stand for re-election as a director on our Board of Directors at the 2010 Annual Meeting of Stockholders to be held on May 20, 2010. Marco Vecchia will replace her as a Class B director nominee.

On March 31, 2010, our Board of Directors appointed Ira Duarte, Director of Accounting, to serve as our principal accounting officer, effective April 1, 2010. Ms. Duarte has served as our Director of Accounting since June 2009. David Price will remain our Chief Financial Officer upon Ms. Duarte's appointment as principal accounting officer. Mr. Price's duties and responsibilities as principal accounting officer will end on April 1, 2010.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

*April 1, 2010*

Cornerstone Therapeutics Inc.

By: */s/ Andrew K. W. Powell*

---

*Name: Andrew K. W. Powell*

*Title: Executive Vice President, General Counsel and Secretary*